Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Z...(Seizures: BIA-2093-301 Study. Poster pre...)

(6). Ben-Menachem E, Gabbai AA, Hufnagel A et al. An Evaluation of Efficacy and Safety of Eslicarbazepine Acetate (ESL) as Add-on Treatment in Adults with Refractory Partial-Onset Seizures: BIA-2093-302 Study. Poster presented at the American Epilepsy Society (AES) Congress, 5-9 December 2009, Seattle, WA, USA.

(7). Gil-Nagel A, Lopes-Lima J, Maia J et al. An Evaluation of Efficacy and Safety of Eslicarbazepine Acetate (ESL) as Add-on Treatment in Adults with Refractory Partial-Onset Seizures: BIA-2093-303 Study. Poster presented at the American Epilepsy Society (AES) Congress, 5-9 December 2009, Seattle, WA, USA.

(8). Elger C, French J, Halasz P et al. An Evaluation of Efficacy and Safety of Eslicarbazepine Acetate as Add-On Treatment in Patients with Partial-Onset Seizures: Pooled Analysis of Three Double Blind Phase III Clinical Studies. Oral presentation at the American Epilepsy Society (AES) Congress, 5-9 December 2009, Seattle, WA, USA.

(9). Halasz P, Elger C, Guekht A et al. Long-Term Treatment of Partial Epilepsy with Eslicarbazepine Acetate (ESL): Results of a One-Year Open-Label Extension to Study BIA-2093-301. Poster presented at the American Epilepsy Society (AES) Congress, 5-9 December 2009, Seattle, WA, USA.

(10). Gabbai AA, Ben-Menachem E, Maia J et al. Long-Term Treatment of Partial Epilepsy with Eslicarbazepine Acetate (ESL): Results of a One-Year Open-Label Extension to Study BIA-2093-302. Poster presented at the American Epilepsy Society (AES) Congress, 5-9 December 2009, Seattle, WA, USA.

(11). Lopes-Lima J, Gil-Nagel A, Maia J et al. Long-Term Treatment of Partial Epilepsy with Eslicarbazepine Acetate (ESL): Results of a One-Year Open-Label Extension to Study BIA-2093-303. Poster presented at the American Epil
'/>"/>